Document is current
Any future updates will be listed below
-
Authors
Galati, Domenico https://orcid.org/0000-0001-5613-9149
Zanotta, Serena https://orcid.org/0000-0003-4917-2076
Capone, Mariaelena https://orcid.org/0000-0002-1352-2532
Madonna, Gabriele https://orcid.org/0000-0001-9395-3190
Mallardo, Domenico https://orcid.org/0000-0002-1081-5313
Romanelli, Marilena
Simeone, Ester
Festino, Lucia https://orcid.org/0000-0002-3035-266X
Sparano, Francesca
Azzaro, Rosa
De Filippi, Rosaria https://orcid.org/0000-0001-7899-3071
Pinto, Antonio https://orcid.org/0000-0002-9425-9026
Paulos, Chrystal M. https://orcid.org/0000-0002-0784-2601
Ascierto, Paolo A. https://orcid.org/0000-0002-8322-475X
-
Funding
Funding for this research was provided by:
Ministero della Salute (M2-2, IT-MOH "Ricerca Corrente")
- License Information
-
More Information
Article History
Received: 3 May 2023
Accepted: 5 May 2023
First Online: 11 May 2023
Declarations
:
: This study was approved by the Ethics Committee of Istituto Nazionale Tumori-IRCCS- Fondazione ‘G. Pascale’, Naples, Italy, protocol number 33/17 oss. All patients provided their written informed consent to participate in this study.
: Consent obtained directly from patient (s).
: PAA has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, and Sanofi. Travel support by Pfizer, Bio-Al Health, and Replimmune. AP declares lectures honoraria from Hoffmann-La Roche AG, Incyte–Italy, Merck Sharp and Dohme, Bristol-Meyers Squibb, and participation to scientific advisory boards for F. Hoffmann-La Roche AG, Merck Sharp, and Dohme, Takeda, and Incyte-Italy. All other authors have declared no conflicts of interest.
